Immunization with Recombinant Plasmodium falciparum Erythrocyte Membrane Protein 1 CIDRα1 Domains Induces Domain Subtype Inhibitory Antibodies

Infection and Immunity
Louise TurnerThomas Lavstsen

Abstract

Plasmodium falciparum malaria pathogenesis is tied to the sequestration of parasites in the microvasculature. Parasite sequestration leading to severe malaria is mediated by P. falciparum erythrocyte membrane protein 1 (PfEMP1) binding to endothelial protein C receptor (EPCR) via its CIDRα1 domains. CIDRα1 domains are targets of naturally acquired immunity, and a vaccine eliciting antibodies inhibiting the EPCR binding of CIDRα1 could potentially prevent disease and death from malaria. CIDRα1 domains have diversified in sequence to escape immune recognition but preserved structure to maintain EPCR binding. The EPCR-binding CIDRα1 domains separate into six major sequence types predicted to form a conserved structure in which only the amino acids essential for EPCR binding are highly conserved. Here, we investigated whether antibodies elicited by vaccination with single or multiple recombinant CIDRα1 domains are able to bind and inhibit diverse CIDRα1 domains. We found that EPCR binding-inhibitory antibodies to CIDRα1 variants closely related to those used for vaccination are readily elicited, whereas antibodies binding distant CIDRα1 variants are sporadically generated and are rarely inhibitory. Despite this, sequence similarity...Continue Reading

References

May 25, 1995·The New England Journal of Medicine·K MarshN Peshu
Apr 1, 1994·Clinical and Experimental Immunology·P H JakobsenB M Greenwood
Mar 23, 2004·Nucleic Acids Research·Robert C Edgar
Jun 3, 2004·Genome Research·Gavin E CrooksSteven E Brenner
Aug 14, 2009·The Journal of Immunology : Official Journal of the American Association of Immunologists·Gerald K K ChamThor G Theander
Sep 24, 2010·PLoS Computational Biology·Thomas S RaskThomas Lavstsen
Nov 17, 2010·The Journal of Immunology : Official Journal of the American Association of Immunologists·Lea BarfodLars Hviid
Mar 14, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Lorenz von SeidleinArjen M Dondorp
May 24, 2012·Proceedings of the National Academy of Sciences of the United States of America·Thomas LavstsenThor G Theander
May 9, 2014·The New England Journal of Medicine·Bronner P GonçalvesPatrick E Duffy
Mar 19, 2015·The New England Journal of Medicine·Karl B SeydelTerrie E Taylor
Oct 24, 2015·The Journal of Infectious Diseases·Haruhiko IshiokaArjen M Dondorp
May 18, 2016·Proceedings of the National Academy of Sciences of the United States of America·Maria BernabeuJoseph D Smith
Jun 30, 2016·EMBO Molecular Medicine·Jakob S JespersenThomas Lavstsen
Sep 27, 2016·Nature Communications·Fu-Lien HsiehMatthew K Higgins
Dec 13, 2016·Trends in Parasitology·Maria Bernabeu, Joseph D Smith
Sep 3, 2017·The Journal of Infectious Diseases·Nicaise Tuikue NdamPhilippe Deloron
Nov 7, 2017·Cell Host & Microbe·Anne KesslerKami Kim

❮ Previous
Next ❯

Citations

Mar 6, 2019·The Journal of Immunology : Official Journal of the American Association of Immunologists·Cyrielle FougerouxPeter Johannes Holst
Sep 19, 2019·Proceedings of the National Academy of Sciences of the United States of America·Frank LennartzMatthew K Higgins

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimalarial Agents (ASM)

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Antimalarial Agents

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Antibody Specificity

Antibodies produced by B cells are highly specific for antigen as a result of random gene recombination and somatic hypermutation and affinity maturation. As the main effector of the humoral immune system, antibodies can neutralize foreign cells. Find the latest research on antibody specificity here.